Oxford BioMedica Plc (OXB) is a gene and cell therapy contract development and manufacturing organization that focuses on developing life-changing treatments for serious diseases. It has built a platform of innovative technologies and capabilities, based on its proprietary lentiviral vector delivery platform LentiVector. Through this technology, the therapeutic DNA is inserted into patients’ cells either in vivo (known as gene therapy) or ex vivo (known as cell therapy).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

OXB is focused on advancing cell and gene therapy through various R&D initiatives, including improving viral vector platforms, optimizing manufacturing processes, and developing next-generation technologies. The company is committed to enhancing the quantity, quality, and cost-effectiveness of viral vectors to benefit patients with high unmet medical needs. Key areas of research include lentiviral platform optimisation, AAV productivity, and manufacturing scale-up to ensure robust, efficient production processes. The R&D unit of Oxford BioMedica Plc is the dedicated innovation department. This unit is responsible for improving viral vector platforms, optimizing manufacturing processes, and developing new technologies to advance the company's capabilities and support partners in bringing transformative therapies to patients. The R&D units of OXB include facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and Bedford, MA, US. These units are responsible for managing the company's R&D activities, including viral vector development and manufacturing, process development, and innovation in cell and gene therapy. As of April 2025, the company had 40 clients and developed 48 client programmes. In FY2025, the company spent GBP5 million on R&D, which, as a percentage of revenue, stood at 2.9%.